Anton P. Porsteinsson, MD: Addressing Trial Design and Symptom Intervention in Alzheimer Disease
The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.
Lynn Kramer, MD: BAN2401 Phase IIb Clinical Study Results
This is the first large late-stage clinical trial to further support the amyloid hypothesis.
Jeff D. Williamson, MD, MHS: SPRINT-MIND Trial Preliminary Results
The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.
Krista Lanctot, PhD: Nabilone Significantly Improves Agitation in Alzheimer Disease
The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.
Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis
Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released
These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.
PET and Clinical Changes in Diagnosis
A prospective cohort study of patients offered amyloid PET as part of their dementia work-up. The results here.
New Hope for Migraine Patients
The FDA has approved a new drug for the prevention of migraines. Will the injectable treatment help reduce the number of days of migraine headaches?
Neurological Consult Using Audiovisual Tools
How effective is the telemedicine versus telephonic approach in acute care?
Parkinson Disease: When There’s No Fight Left
An update on the prevalence and features of demoralization in patients with PD.
Cerebral Microbleeds and Dementia
5 key facts about cerebral microbleeds and risk of future cognitive impairment.
New Research on Secondary Progressive Multiple Sclerosis
5 important facts from a recent double-blind, randomized phase 3 study about siponimod in SPMS.
Hideki Garren, MD, PhD: Past and Future Ocrelizumab Analyses
The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).
Lilyana Amezcua, MD: Better Understanding MS in the Hispanic Community
The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.
Gregory Day, MD, MSc: The Challenge of Alzheimer Diagnosis
The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.
Alberto Espay, MD, MSc: Modifying Thought About Parkinson Disease
The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.
Ralph Kern, MD, MHSc: The State of Therapies for ALS
The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.
BMI, Sitting, and the Risk of Parkinson Disease
A study examines a possible link between lifestyle and onset of PD.
Practice Guideline Update: 5 Important Facts About MCI
Here: the most notable changes in the new AAN guideline on mild cognitive impairment.
Retinal Signs and Cognitive Decline Over 20 Years
A study looked at changes in retinal signs with fundus photography and their association with cognitive decline.
Hemorrhage Risk and Anticoagulation: Implications of Brain Microbleeds
5 key facts about the association between cerebral microbleeds and risk of future intracerebral hemorrhage in patients with afib who take oral anticoagulants after ischemic stroke.
Antihypertensive Medications and Survival After Stroke or TIAs
A large retrospective cohort study of over 12,000 patients from 40 hospitals looked at the risk of death following stroke or TIA, and whether patients had been prescribed antihypertensive medications.
Exercise and Alzheimer Disease
A large study evaluated exercise and its effects on cognitive function in patients with, or at risk for, Alzheimer disease.
Caffeine Metabolism in PD
Lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data that support the neuro-protective properties of caffeine.
Acute Carbon Monoxide Poisoning and MRI Lesions: 5 Important Facts
In this 6-minute video presentation, Dr. Andrew Wilner describes the epidemiology and pathophysiology of carbon monoxide poisoning and reviews the implications of a recently published observational study.
NORSE: 5 Important Facts
Although rare, new onset refractory status epilepticus can be life threatening if not identified quickly.
Midlife Triglyceride Levels and Alzheimer Disease Pathology
Findings from a study lends credence to the role of lipids in the early stages of Alzheimer disease.
Weight Loss and Parkinson Disease
An incident, population-based prospective cohort study examined weight changes over time in patients with Parkinson disease.
Stroke Associated Infection
Researchers conducted a retrospective analysis of patients with acute stroke and evaluated the effect of infection during the hospitalization period.
2 Clarke Drive Cranbury, NJ 08512